Diabetic cardiomyopathy;Diyabetik kardiyomiyopati

Anadolu Kardiyoloji Dergisi

Volumn 11, Issue 8, 2011, Pages 732-737

  Acar, Eser ^a   Ural, Dilek ^a   Bildirici, Ulaş ^a   Şahin, Tayfun ^a   Yilmaz, Irem ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Diabetic cardiomyopathy; Diastolic dysfunction; Echocardiography

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE 711; ALANINE AMINOTRANSFERASE 946; ALPHA TOCOPHEROL; AMINOGUANIDINE; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CARDIAC AGENT; CARVEDILOL; COPPER; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; FATTY ACID; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; METOPROLOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLACEBO; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR; TRIENTINE; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ANGINA PECTORIS; APOPTOSIS; AUTONOMIC NEUROPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; COPPER METABOLISM; CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FATTY ACID METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; MICROANGIOPATHY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

DIABETIC CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; HUMANS;

EID: 83455166430     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2011.196     Document Type: Review

References (50)

1. Silink M. Diabetes atlas foreword. International Diabetes Federation. 2009 August. Available from: URL: http://www.idf.org/ diabetesatlas/foreword.
2. Khavandi K, Khavandi A, Asghar O, Greenstein A, Withers S, Heagerty AM, et al. Diabetic cardiomyopathy-a distinct disease? Best Pract Res Clin Endocrinol Metab 2009; 23: 347-60. [CrossRef]
3. Cohen-Solal A, Beauvais F, Loqeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 2008; 14: 615-25. [CrossRef]
4. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail 2010; 16: 971-9. [CrossRef]
5. Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 2003; 26: 2791-5. [CrossRef]
6. Rubler S, Dlugash J, Yüceoǧlu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602. [CrossRef]
7. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23. [CrossRef]
8. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008; 121: 748-57. [CrossRef]
9. Wynne J, Braunwald E. The cardiomyopathies. In: Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Braunwald's Heart Disease. 7th ed. PA: Saunders Elsevier; 2008. pp. 1659-96.
10. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977; 60: 884-99. [CrossRef]
11. Maya L, Villarreal FJ. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol 2010; 48: 524-9. [CrossRef]
12. Wold LE, Relling DP, Colligan PB, Scott GI, Hintz KK, Ren BH, et al. Characterization of contractile function in diabetic hypertensive cardiomyopathy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001; 33: 1719-26. [CrossRef]
13. Bildirici U, Ural D, Acar E, Aǧaçdiken A, Ural E. Diagnostic value of poor R-wave progression in electrocardiograms for diabetic cardiomyopathy in type 2 diabetic patients. Clin Cardiol 2010; 33: 559-64. [CrossRef]
14. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect 2002; 15: 197-205. [CrossRef]
15. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol 2011; 48: 173-81. [CrossRef]
16. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, et al. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003; 112: 1049-57. [CrossRef]
17. Susic D, Varagic J, Ahn J, Frohlich ED. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4: 97-101. [CrossRef]
18. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004; 64: 459-70. [CrossRef]
19. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87: 1123-32.
20. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. Diabetesinduced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 2000; 32: 1621-9. [CrossRef]
21. Yoshimura M, Anzawa R, Mochizuki S. Cardiac metabolism in diabetes mellitus. Curr Pharm Des 2008; 14: 2521-6. [CrossRef]
22. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
23. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998; 180: 53-7. [CrossRef]
24. Boudina S, Abel ED. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology 2006; 21: 250-8. [CrossRef]
25. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107: 539-57. [CrossRef]
26. Yazaki Y, Isobe M, Takahashi W, Kitabayashi H, Nishiyama O, Sekiguchi M, et al. Assessment of myocardial fatty acid abnormalities in patients with idiopathic dilated cardiomyopathy using I123 BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart 1999; 81: 153-9.
27. Malhotra A, Sanghi V. Regulation of contractile proteins in diabetic heart. Cardiovasc Res 1997; 34: 34-40. [CrossRef]
28. Takeda N, Nakamura I, Hatanaka T, Ohkubo T, Nagano M. Myocardial mechanical and myosin isoenzyme alterations in streptozotocin-diabetic rats. Jpn Heart J 1988; 29: 455-63. [CrossRef]
29. Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, et al. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol 2002; 282: 138-48.
30. Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2011; 28. DOI 10.1007/ s10741-011-9257-z. [CrossRef]
31. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res 1995; 77: 638-43.
32. Debonoa M, Cachia E. The impact of cardiovascular autonomic neuropathy in diabetes: is it associated with left ventricular dysfunction? Auton Neurosci 2007; 132: 1-7. [CrossRef]
33. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000; 32: 817-30. [CrossRef]
34. Walter RM Jr, Uriu-Hare JY, Olin KL, Oster MH, Anawalt BD, Critchfield JW, et al. Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care 1991; 14: 1050-6. [CrossRef]
35. Islam KN, Takahashi M, Higashiyama S, Myint T, Uozumi N. Fragmentation of ceruloplasmin following non-enzymatic glycation reaction. J Biochem 1995; 118: 1054-60.
36. Yim MB, Yim HS, Lee C, Kang SO, Chock PB. Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci 2001; 928: 48-53. [CrossRef]
37. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25: 543-67. [CrossRef]
38. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002; 98: 33-9. [CrossRef]
39. Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J 1989; 118: 1000-12. [CrossRef]
40. Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C, et al. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 2005; 22: 1720-5. [CrossRef]
41. Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003; 41: 611-7. [CrossRef]
42. Di Bello V, Talarico L, Picano E, Di Muro C, Landini L, Paterni M, et al. Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. J Am Coll Cardiol 1995: 25: 1408-15. [CrossRef]
43. Chung J, Abraszewski P, Yu X, Liu W, Krainik AJ, Ashford M, et al. Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control. J Am Coll Cardiol 2006; 47: 384-90. [CrossRef]
44. Fonseca CG, Dissanayake AM, Doughty RN, Whalley GA, Gamble GD, Cowan BR, et al. Three-dimensional assessment of left ventricular systolic strain in patients with type 2 diabetes mellitus, diastolic dysfunction, and normal ejection fraction. Am J Cardiol 2004; 94: 1391-5. [CrossRef]
45. Adler AI, Neil HA, Manley SE, Holman RR, Turner RC. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J 1999; 138: 353-9. [CrossRef]
46. Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A, et al. Diabetic cardiomyopathy. Clin Sci (Lond) 2009; 116: 741-60. [CrossRef]
47. Okoshi K, Guimarães JF, Di Muzio BP, Fernandes AA, Okoshi MP. Diabetic cardiomyopathy. Arq Bras Endocrinol Metabol 2007; 51: 160-7. [CrossRef]
48. Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, Masuyama T. Role of activated rennin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients-reversal by chronic angiotensin II type 1A receptor blockade. Circ J 2007; 71: 524-9. [CrossRef]
49. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29: 2388-442. [CrossRef]
50. Khullar M, Al-Shudiefat AA, Ludke A, Binepal G, Singal PK. Oxidative stress: a key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol 2010; 88: 233-40. [CrossRef]